Advertising
Showing 1 to 15 of 25 entries
WATCH
It made a ton of money since Covid, but it hasn't done much with that cash and didn't develop a pill treatment like Pfizer. He wishes they would buy weaker biotechs with that cash to grow. He expects/hope that.
Pharma & Healthcare
DON'T BUY
Fallen a lot recently. If we believe that Covid becomes endemic and we don't all need shots, what's going to happen to MRNA? Crazy cheap at 8-9x next year's earnings, beautiful balance sheet, technology works, but what's the next catalyst? He tends to stay away from biotechs and pharmas, as the science is too hard to understand.
Pharma & Healthcare
COMMENT
Among the 10 top performers on the S&P of 2021 #3, up 143%. He doubts MRNA can repeat this increase unless everybody gets a fourth dose of their vaccine or can diversify into, say, cancer vaccines. He loves management, but the stock isn't pricing in the chance the Omicron will come and go quickly (and result in a bad kind of herd immunity).
Pharma & Healthcare
BUY
Believes Moderna is example of how pharmaceuticals changing (increased vaccine turnaround time). Good buying opportunity at current price. Strong pipeline in many different areas. Opportunity to use Covid-19 education towards other diseases/viruses.
Pharma & Healthcare

Unlock the Weekly Buzzing Stocks

Become a member Or, Sign In
TOP PICK
One of the best drug pipeline in the industry and trading under 10x earnings according to Stephen Weiss. Social media mentions are up 1056% over the last 7 days.
Pharma & Healthcare
DON'T BUY
Got hammered today, but they need to prove they can deliver vaccines to market.
Pharma & Healthcare
BUY
It's down 5% today, but he has conviction for it. Less than 10x earnings this year and next, and boasts one of the best drug pipelines in the industry.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 07/21, Up 125%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with MNRA has triggered its stop at $300. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment return of 78%.
Pharma & Healthcare
SELL
He owned it and sold it way too early. All the good news is in this stock for the next two years. It was well ahead of the fundamentals. Watch for another opportunity with them. It's fully valued right now.
Pharma & Healthcare
BUY

It had a huge run. When the pandemic ends, the prices on their shots will leap from $25 to $150-200 which is normal for booster shots. Think of the profitability and their pipeline of 34 drugs.

Pharma & Healthcare
DON'T BUY
In the news for their vaccine. It's pretty much all their business right now. Total revenue was $60M, but their market cap is $170B. The question is, are their legs with the vaccine franchise. They have lots of drugs in their pipeline, but there is a lot of risk.
Pharma & Healthcare

Unlock the Weekly Buzzing Stocks

Become a member Or, Sign In
TOP PICK
They have done well with their Covid vaccine. Their targeted cancer vaccine is expected to generate even more revenues. Can do a lot with its formulation. Has many drugs in the pipeline. Social media mentions are up 192%.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 08/21, Up 213.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA is progressing well. We recommend trailing up the stop (from $175) to $300. Along with the previous recommendation to cover half the position, this would all but guarantee a net investment return of 78% if triggered.
Pharma & Healthcare
BUY
Their targeted cancer vaccines will dwarf their revenues from even Covid. These are really smart guys and they're making tons of money.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 08/21, Up 76.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRN is progressing well. We now recommend trailing up the stop (from $134) to $175. If triggered, this would all but guarantee a net investment return of 31%, when considering our previous recommendation to cover 50% of the holding.
Pharma & Healthcare
Showing 1 to 15 of 25 entries

Moderna(MRNA-Q) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 11

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 5

Total Signals / Votes : 16

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, 16 stock analysts published opinions about MRNA-Q. 11 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Moderna.

Is Moderna a good investment or a top pick?

Moderna was recommended as a Top Pick by on . Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

16 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2022-01-27, Moderna (MRNA-Q) stock closed at a price of $148.12.